Journal ArticleDOI
Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
Kiyoshi Arai,Tsuyoshi Homma,Yuka Morikawa,Naoko Ubukata,Hiyoyuki Tsuruoka,Aoki Kazumasa,Hirokazu Ishikawa,Makoto Mizuno,Toshio Sada +8 more
Reads0
Chats0
TLDR
It is indicated that CS-3150 is a selective and highly potent mineralocorticoid receptor antagonist with long-lasting oral activity and could be useful for the treatment of hypertension, cardiovascular and renal disorders.About:
This article is published in European Journal of Pharmacology.The article was published on 2015-08-15. It has received 89 citations till now. The article focuses on the topics: Mineralocorticoid receptor & Eplerenone.read more
Citations
More filters
Journal ArticleDOI
30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development.
Peter Kolkhof,Lars Bärfacker +1 more
TL;DR: Novel non-steroidal MRAs such as apararenone, esaxerenone and finerenone are in late-stage clinical trials in patients with heart failure, chronic kidney disease, hypertension and liver disease and the history of the various generations of MRAs is reflected.
Journal ArticleDOI
CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.
TL;DR: Results indicate that chronic treatment with CS-3150 exerts antihypertensive and cardiorenal protective effects in a DS hypertensive rat model, and its potency is much superior to that of spironolactone or eplerenone.
Journal ArticleDOI
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial
TL;DR: In this article , the authors report incidences and risk factors for hyperkalemia with finerenone and placebo in the FIDELIO-DKD trial and conclude that routine potassium monitoring and hyper-alemia management strategies minimized the impact of hyper kalemia, providing a basis for clinical use of fine renone.
Journal ArticleDOI
Esaxerenone: First Global Approval
TL;DR: In January 2019, based on positive results from a phase III trial conducted in Japan in patients with essential hypertension, esaxerenone received marketing approval in Japan for the treatment of hypertension.
Journal ArticleDOI
CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats.
TL;DR: It is demonstrated that CS-3150 not only prevents but also ameliorates hypertension and renal injury in DOCA rats and may have potential to promote regression of renal injury.
References
More filters
Journal ArticleDOI
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Bertram Pitt,Faiez Zannad,Willem J. Remme,Robert J. Cody,Alain Castaigne,Alfonso Perez,Jolie Palensky,Janet Wittes +7 more
TL;DR: Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
Journal ArticleDOI
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Bertram Pitt,Willem J. Remme,Faiez Zannad,James D. Neaton,Felipe Martinez,Barbara Roniker,Richard Bittman,Steve Hurley,Jay H. Kleiman,Marjorie Gatlin +9 more
TL;DR: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Journal ArticleDOI
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
Faiez Zannad,John J.V. McMurray,Henry Krum,Dirk J. van Veldhuisen,Karl Swedberg,Harry Shi,John Vincent,Stuart J. Pocock,Bertram Pitt +8 more
TL;DR: Eplerenone, as compared with placebo, reduced both the risk of death and therisk of hospitalization among patients with systolic heart failure and mild symptoms.
Journal ArticleDOI
Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Paul Milliez,Xavier Girerd,Pierre-François Plouin,Jacques Blacher,Michel E. Safar,Jean-Jacques Mourad +5 more
TL;DR: Patients presenting with PA experienced more cardiovascular events than did EHT patients independent of blood pressure, and the presence of PA should be detected, not only to determine the cause of HTN, but also to prevent such complications.
Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
B. Pitt,W. Remme,F. Zannad,J. Neaton,F Martinez,B. Roniker,R Bittman,S Hurley,J Kleiman,M Gatlin +9 more